Free Trial
NASDAQ:IDXX

IDEXX Laboratories (IDXX) Stock Price, News & Analysis

IDEXX Laboratories logo
$630.56 -1.66 (-0.26%)
Closing price 04:00 PM Eastern
Extended Trading
$630.46 -0.10 (-0.02%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About IDEXX Laboratories Stock (NASDAQ:IDXX)

Advanced

Key Stats

Today's Range
$619.00
$636.34
50-Day Range
$520.87
$682.78
52-Week Range
$356.14
$688.12
Volume
266,134 shs
Average Volume
404,429 shs
Market Capitalization
$50.44 billion
P/E Ratio
52.50
Dividend Yield
N/A
Price Target
$649.44
Consensus Rating
Moderate Buy

Company Overview

IDEXX Laboratories Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
84th Percentile Overall Score

IDXX MarketRank™: 

IDEXX Laboratories scored higher than 84% of companies evaluated by MarketBeat, and ranked 168th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    IDEXX Laboratories has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 6 buy ratings, 3 hold ratings, and no sell ratings.

  • Upside/Downside

    The consensus price target for IDEXX Laboratories is close to its current price, suggesting limited near-term upside or downside.

  • Amount of Analyst Coverage

    IDEXX Laboratories has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about IDEXX Laboratories' stock forecast and price target.
  • Earnings Growth

    Earnings for IDEXX Laboratories are expected to grow by 13.83% in the coming year, from $11.93 to $13.58 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of IDEXX Laboratories is 52.50, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 281.43.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of IDEXX Laboratories is 52.50, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 75.67.

  • Price to Earnings Growth Ratio

    IDEXX Laboratories has a PEG Ratio of 4.09. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    IDEXX Laboratories has a P/B Ratio of 32.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about IDEXX Laboratories' valuation and earnings.
  • Percentage of Shares Shorted

    2.59% of the float of IDEXX Laboratories has been sold short.
  • Short Interest Ratio / Days to Cover

    IDEXX Laboratories has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in IDEXX Laboratories has recently increased by 12.02%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    IDEXX Laboratories does not currently pay a dividend.

  • Dividend Growth

    IDEXX Laboratories does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.59% of the float of IDEXX Laboratories has been sold short.
  • Short Interest Ratio / Days to Cover

    IDEXX Laboratories has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in IDEXX Laboratories has recently increased by 12.02%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    IDEXX Laboratories has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.02 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 25 news articles for IDEXX Laboratories this week, compared to 27 articles on an average week.
  • Search Interest

    Only 6 people have searched for IDXX on MarketBeat in the last 30 days. This is a decrease of -68% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, IDEXX Laboratories insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $34,293,468.00 in company stock.

  • Percentage Held by Insiders

    Only 0.98% of the stock of IDEXX Laboratories is held by insiders.

  • Percentage Held by Institutions

    87.84% of the stock of IDEXX Laboratories is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about IDEXX Laboratories' insider trading history.
Receive IDXX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IDEXX Laboratories and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

IDXX Stock News Headlines

IDEXX Laboratories (NASDAQ:IDXX) Lowered to Buy Rating by Wall Street Zen
Reviewing Sintx Technologies (NASDAQ:SINT) and IDEXX Laboratories (NASDAQ:IDXX)
Why More Investors Are Using Family Trusts to Protect Their Wealth
For many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensuring wealth is passed on according to your wishes. Trusts may also provide shielding from creditors and lawsuits while offering potential tax advantages—especially with estate tax thresholds set to decrease in 2026. If you’re considering whether a family trust is right for you, speaking with a fiduciary financial advisor can help you decide the best path forward. We’ve created a free tool that matches you with vetted advisors in your area—each legally bound to act in your best interest.tc pixel
See More Headlines

IDXX Stock Analysis - Frequently Asked Questions

IDEXX Laboratories' stock was trading at $413.44 on January 1st, 2025. Since then, IDXX shares have increased by 52.5% and is now trading at $630.56.

IDEXX Laboratories, Inc. (NASDAQ:IDXX) issued its quarterly earnings results on Monday, August, 4th. The company reported $3.63 EPS for the quarter, topping analysts' consensus estimates of $3.28 by $0.35. The company's revenue for the quarter was up 10.6% on a year-over-year basis.
Read the conference call transcript
.

Shares of IDXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that IDEXX Laboratories investors own include Tesla (TSLA), Broadcom (AVGO), Applied Materials (AMAT), HubSpot (HUBS), ASML (ASML), CrowdStrike (CRWD) and Cadence Design Systems (CDNS).

Company Calendar

Last Earnings
8/04/2025
Today
9/29/2025
Next Earnings (Estimated)
10/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED INSTRUMENTS
Sub-Industry
Health Care Equipment
Current Symbol
NASDAQ:IDXX
CIK
874716
Employees
11,000
Year Founded
1983

Price Target and Rating

High Price Target
$785.00
Low Price Target
$520.00
Potential Upside/Downside
+3.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
10 Analysts

Profitability

EPS (Trailing Twelve Months)
$12.01
Trailing P/E Ratio
52.50
Forward P/E Ratio
52.85
P/E Growth
4.09
Net Income
$887.87 million
Net Margins
24.41%
Pretax Margin
30.41%
Return on Equity
64.42%
Return on Assets
29.89%

Debt

Debt-to-Equity Ratio
0.31
Current Ratio
1.11
Quick Ratio
0.79

Sales & Book Value

Annual Sales
$3.90 billion
Price / Sales
12.94
Cash Flow
$12.40 per share
Price / Cash Flow
50.86
Book Value
$19.48 per share
Price / Book
32.37

Miscellaneous

Outstanding Shares
80,000,000
Free Float
79,221,000
Market Cap
$50.44 billion
Optionable
Optionable
Beta
1.56

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:IDXX) was last updated on 9/29/2025 by MarketBeat.com Staff
From Our Partners